Lin Y - Search Results

1

CD56^dim CD16^- Natural Killer Cell Profiling in Melanoma Patients Receiving a Cancer Vaccine and Interferon-α.

Vujanovic L, Chuckran C, Lin Y, Ding F, Sander CA, Santos PM, Lohr J, Mashadi-Hossein A, Warren S, White A, Huang A, Kirkwood JM, Butterfield LH. Vujanovic L, et al. Among authors: lin y. Front Immunol. 2019 Jan 29;10:14. doi: 10.3389/fimmu.2019.00014. eCollection 2019. Front Immunol. 2019. PMID: 30761123 Free PMC article.

2

Multiple antigen-engineered DC vaccines with or without IFNα to promote antitumor immunity in melanoma.

Butterfield LH, Vujanovic L, Santos PM, Maurer DM, Gambotto A, Lohr J, Li C, Waldman J, Chandran U, Lin Y, Lin H, Tawbi HA, Tarhini AA, Kirkwood JM. Butterfield LH, et al. Among authors: lin y, lin h. J Immunother Cancer. 2019 Apr 24;7(1):113. doi: 10.1186/s40425-019-0552-x. J Immunother Cancer. 2019. PMID: 31014399 Free PMC article. Clinical Trial.

3

Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab.

Tarhini AA, Edington H, Butterfield LH, Lin Y, Shuai Y, Tawbi H, Sander C, Yin Y, Holtzman M, Johnson J, Rao UN, Kirkwood JM. Tarhini AA, et al. Among authors: lin y. PLoS One. 2014 Feb 3;9(2):e87705. doi: 10.1371/journal.pone.0087705. eCollection 2014. PLoS One. 2014. PMID: 24498358 Free PMC article.

4

Melanoma antigen-specific effector T cell cytokine secretion patterns in patients treated with ipilimumab.

Najjar YG, Ding F, Lin Y, VanderWeele R, Butterfield LH, Tarhini AA. Najjar YG, et al. Among authors: lin y. J Transl Med. 2017 Feb 21;15(1):39. doi: 10.1186/s12967-017-1140-9. J Transl Med. 2017. PMID: 28222797 Free PMC article. Clinical Trial.

5

Safety and efficacy of the antiganglioside GD3 antibody ecromeximab (KW2871) combined with high-dose interferon-α2b in patients with metastatic melanoma.

Tarhini AA, Moschos SJ, Lin Y, Lin HM, Sander C, Yin Y, Venhaus R, Gajewski TF, Kirkwood JM. Tarhini AA, et al. Among authors: lin hm, lin y. Melanoma Res. 2017 Aug;27(4):342-350. doi: 10.1097/CMR.0000000000000353. Melanoma Res. 2017. PMID: 28489678 Clinical Trial.

6

Long term impact of CTLA4 blockade immunotherapy on regulatory and effector immune responses in patients with melanoma.

Retseck J, Nasr A, Lin Y, Lin H, Mendiratta P, Butterfield LH, Tarhini AA. Retseck J, et al. Among authors: lin y, lin h. J Transl Med. 2018 Jul 4;16(1):184. doi: 10.1186/s12967-018-1563-y. J Transl Med. 2018. PMID: 29973204 Free PMC article.

7

Neoadjuvant Pembrolizumab and High-Dose IFNα-2b in Resectable Regionally Advanced Melanoma.

Najjar YG, McCurry D, Lin H, Lin Y, Zang Y, Davar D, Karunamurthy A, Drabick JJ, Neves RI, Butterfield LH, Ernstoff MS, Puzanov I, Skitzki JJ, Bordeaux J, Summit IB, Bender JO, Kim JY, Chen B, Sarikonda G, Pahuja A, Tsau J, Alfonso Z, Laing C, Pingpank JF, Holtzman MP, Sander C, Rose A, Zarour HM, Kirkwood JM, Tarhini AA. Najjar YG, et al. Among authors: lin y, lin h. Clin Cancer Res. 2021 Aug 1;27(15):4195-4204. doi: 10.1158/1078-0432.CCR-20-4301. Epub 2021 Mar 22. Clin Cancer Res. 2021. PMID: 33753453 Free PMC article.

8

Dendritic cell vaccines targeting tumor blood vessel antigens in combination with dasatinib induce therapeutic immune responses in patients with checkpoint-refractory advanced melanoma.

Storkus WJ, Maurer D, Lin Y, Ding F, Bose A, Lowe D, Rose A, DeMark M, Karapetyan L, Taylor JL, Chelvanambi M, Fecek RJ, Filderman JN, Looney TJ, Miller L, Linch E, Lowman GM, Kalinski P, Butterfield LH, Tarhini A, Tawbi H, Kirkwood JM. Storkus WJ, et al. Among authors: lin y. J Immunother Cancer. 2021 Nov;9(11):e003675. doi: 10.1136/jitc-2021-003675. J Immunother Cancer. 2021. PMID: 34782430 Free PMC article. Clinical Trial.

9

Safety and immunogenicity of vaccination with MART-1 (26-35, 27L), gp100 (209-217, 210M), and tyrosinase (368-376, 370D) in adjuvant with PF-3512676 and GM-CSF in metastatic melanoma.

Tarhini AA, Leng S, Moschos SJ, Yin Y, Sander C, Lin Y, Gooding WE, Kirkwood JM. Tarhini AA, et al. Among authors: lin y. J Immunother. 2012 May;35(4):359-66. doi: 10.1097/CJI.0b013e31825481fe. J Immunother. 2012. PMID: 22495394 Free PMC article. Clinical Trial.

10

Dasatinib promotes the expansion of a therapeutically superior T-cell repertoire in response to dendritic cell vaccination against melanoma.

Lowe DB, Bose A, Taylor JL, Tawbi H, Lin Y, Kirkwood JM, Storkus WJ. Lowe DB, et al. Among authors: lin y. Oncoimmunology. 2014 Jan 1;3(1):e27589. doi: 10.4161/onci.27589. Epub 2014 Feb 27. Oncoimmunology. 2014. PMID: 24734217 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

52,502 results

Search Page

Filters